ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Neuropeptide Y-Graphene Oxide Complexes Inhibit Amygdala NPY-Receptor Expressing Glutamatergic Pathways and Selectively Remove Aversive Memory In Vivo.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Therapeutic needs to modulate brain circuits highlight graphene-based materials (GBMs) as an emerging tool to engineer specific interventions to treat neuro-diseases. In this context, graphene oxide (GO) nanosheets offer new drug delivery strategies to reach neural cells and signaling networks selectively. To complex and transport neuropeptide Y (NPY), GO was engineered as GO:NPY, and its activity was investigated in regulating excitatory neurotransmission in NPY-positive synaptic pathways, when delivered to the amygdala, a structure mediating fear memory responses. First, it was shown that in vitro GO:NPY specifically and selectively inhibited glutamate release and suppressed synaptic enhancement via NPY receptors. In a rat model of anxiety disorder, when injected into the amygdala, GO:NPY suppressed contextual fear memory responses via activation of NPY receptors in specific synaptic pathways. This easy-to-tune GBM-based nanoplatforms promise advances in co-delivery vectors preserving the synaptic specificity needed for treating specific pathological conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.